NIA is extremely excited to announce its first ever Biotech Stock Suggestion: Citius Pharmaceuticals, Inc. (CTXR). The company was just listed to the NASDAQ for the first time in August and remains undiscovered at this time. CTXR at $3.76 per share reminds us very much of HIVE trading at $0.74 per share six weeks ago – in terms of having potential to make explosive short-term gains. Less than one week ago, CTXR announced that it received “Fast Track” status from the FDA for its Mino-Lok product and is currently beginning its Phase 3 trials!
Currently, CTXR at $3.76 per share has an extremely low market cap of only $31 million, considering that Mino-Lok is the only product addressing a HUGE unmet market that is estimated to be worth $750 million in the U.S. alone! Central venous catheters (CVCs) are life-saving vascular access ports in patients requiring long-term intravenous therapy. However, of the approximately 7 million CVCs used annually about 500,000 or 7% become infected leading to serious, life threatening infections known as catheter-related blood stream infections (CRBSIs).
CTXR’s Mino-Lok is an antibiotic lock solution used to treat patients with CRBSIs. Currently, the standard of care in the management of CRBSIs consists of removing the infected CVC and replacing it with a new catheter at a different vascular access site. These procedures are costly and 15% to 20% of the procedures are associated with significant morbidity. There are currently no approved therapies to salvage infected CVCs!
Often, the removal of the CVC and reinsertion of a new CVC at a different site may be difficult, or even impossible, because of the unavailability of other accessible vascular sites and the need to maintain infusion therapy. Critically ill patients with short-term catheters often have underlying coagulopathy, where the blood’s ability to clot is impaired. This condition would make reinsertion of a new CVC at a different site risky in terms of mechanical complications.
The FDA only designates Fast Track status to products that treat serious or life-threatening conditions and fill an unmet medical need. It makes Mino-Lok eligible for priority review to shorten the FDA review process from ten months to only six months!
If CTXR receives FDA approval for Mino-Lok, NIA predicts that CTXR will become its next stock to achieve explosive short-term gains similar to the 812.2% rally that HIVE just made! CTXR is located near NIA in NJ and what makes us extremely confident in CTXR’s ability to execute is the fact that its Chairman Leonard Mazur recently added 432,400 shares to his position at an average price of $4.09 per share. There is nothing more bullish than the Chairman of a company investing $1.77 million into his own stock to help fund Phase 3 trials!
Take a look at these other biotech stocks that received FDA Fast Track status in recent months:
Pluristem (PSTI) received Fast Track status on September 18, 2017 and the stock rose from $1.23 per share to a high in October of $2.12 per share for a gain of 72.4% in six weeks.
Iovance Biotherapeutics (IOVA) received Fast Track status on August 31, 2017 and the stock rose from $4.50 per share to a high in September of $8.60 per share for a gain of 91.1% in one month.
UroGen Pharma (URGN) received Fast Track status on August 29, 2017 and the stock rose from $18.04 per share to a high yesterday of $38.38 per share for a gain of 112.7% in two months.
CTXR has the lowest market cap out of every biotech stock we are aware of that received Fast Track status from the FDA in 2017!
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from a third-party for covering CTXR of $20,000 cash. Never make investment decisions based on anything NIA says. This message is meant for informational and educational purposes only and does not provide investment advice.